Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, randomised, double blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of single and repeat doses of AMP945 administered orally to healthy adult volunteers

Next Previous
X
Search
Trial Profile

A Phase I, randomised, double blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of single and repeat doses of AMP945 administered orally to healthy adult volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Mar 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Narmafotinib (Primary)
  • Indications Idiopathic CD4-positive T-lymphocytopenia; Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors Amplia Therapeutics Limited

    • Most Recent Events

    • 23 Feb 2023 According to Amplia media release, Dr. Terrie-Anne Cock from Amplia Therapeutics will present a lecture at the 2nd Next Generation Kinase Inhibitors Summit currently underway in Boston, USA.
    • 13 Apr 2022 Results presented at the 113th Annual Meeting of the American Association for Cancer Research
    • 15 Sep 2021 Status changed from not yet recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top